Cargando…

Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy

Natural killer (NK) cells mediate potent anti-tumor responses, which makes them attractive targets for immunotherapy. The anti-tumor response of endogenous- or allogeneic NK cells can be enhanced through clinically available monoclonal antibodies that mediate antibody-dependent cellular cytotoxicity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beelen, Nicky A., Ehlers, Femke A. I., Bos, Gerard M. J., Wieten, Lotte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025219/ https://www.ncbi.nlm.nih.gov/pubmed/36261539 http://dx.doi.org/10.1007/s00262-022-03299-x

Ejemplares similares

Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids
por: Beelen, Nicky A., et al.
Publicado: (2023)

Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A
por: Mahaweni, Niken M., et al.
Publicado: (2018)

ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response
por: Ehlers, Femke A. I., et al.
Publicado: (2021)

Activated Natural Killer Cells Withstand the Relatively Low Glucose Concentrations Found in the Bone Marrow of Multiple Myeloma Patients
por: Ehlers, Femke A. I., et al.
Publicado: (2021)

HLA Class I Molecules as Immune Checkpoints for NK Cell Alloreactivity and Anti-Viral Immunity in Kidney Transplantation
por: Duygu, Burcu, et al.
Publicado: (2021)

Polymorphic differences within HLA‐C alleles contribute to alternatively spliced transcripts lacking exon 5
por: Ehlers, Femke A. I., et al.
Publicado: (2022)

NKG2A Expression Is Not per se Detrimental for the Anti-Multiple Myeloma Activity of Activated Natural Killer Cells in an In Vitro System Mimicking the Tumor Microenvironment
por: Mahaweni, Niken M., et al.
Publicado: (2018)

Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions
por: Mahaweni, Niken M., et al.
Publicado: (2018)

Defucosylation of Tumor-Specific Humanized Anti-MUC1 Monoclonal Antibody Enhances NK Cell-Mediated Anti-Tumor Cell Cytotoxicity
por: Gong, Ying, et al.
Publicado: (2021)

Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A
por: Sarkar, Subhashis, et al.
Publicado: (2015)

Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages
por: Ehlers, Femke A. I., et al.
Publicado: (2023)

Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies
por: Seidel, Ursula J. E., et al.
Publicado: (2013)

CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
por: Giraudo, Lidia, et al.
Publicado: (2023)

Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors
por: Van Elssen, Catharina, et al.
Publicado: (2020)

The Impact of HLA Class I-Specific Killer Cell Immunoglobulin-Like Receptors on Antibody-Dependent Natural Killer Cell-Mediated Cytotoxicity and Organ Allograft Rejection
por: Rajalingam, Raja
Publicado: (2016)

Regulation of T cell lymphokine production by killer cell inhibitory receptor recognition of self HLA class I alleles
Publicado: (1996)

The Immunomodulatory Role of Hypoxic Tumor-Derived Extracellular Vesicles
por: Beaumont, Joel E. J., et al.
Publicado: (2022)

Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer
por: Matsuzaki, Junko, et al.
Publicado: (2022)

KIR/HLA genotype combinations are determinants of Natural Killer (NK) cell mediated antibody-dependent cellular cytotoxicity (ADCC) potency
por: Parsons, MS, et al.
Publicado: (2012)

Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer
por: van Gelder, Michel, et al.
Publicado: (2016)

Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28
por: Mariotti, F.R., et al.
Publicado: (2020)

Cytotoxic T cell recognition of an endogenous class I HLA peptide presented by a class II HLA molecule
Publicado: (1990)

iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity
por: Suzuki, Daisuke, et al.
Publicado: (2019)

Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19
por: Demaria, Olivier, et al.
Publicado: (2020)

Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer
por: Buckle, Irina, et al.
Publicado: (2021)

Recruitment, Infiltration, and Cytotoxicity of HLA-Independent Killer Lymphocytes in Three-Dimensional Melanoma Models
por: Iaia, Ilenia, et al.
Publicado: (2021)

Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
por: Fenerty, Kathleen E., et al.
Publicado: (2018)

Hypoxia Induced Impairment of NK Cell Cytotoxicity against Multiple Myeloma Can Be Overcome by IL-2 Activation of the NK Cells
por: Sarkar, Subhashis, et al.
Publicado: (2013)

Killer Cell Inhibitory Receptor Recognition of Human Leukocyte Antigen (HLA) Class I Blocks Formation of a pp36/PLC-γ Signaling Complex in Human Natural Killer (NK) Cells
por: Valiante, Nicholas M., et al.
Publicado: (1996)

Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy
por: Kwon, Hyung-Joon, et al.
Publicado: (2017)

Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
por: Cao, Yuqing, et al.
Publicado: (2020)

HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies
por: Morandi, Fabio, et al.
Publicado: (2022)

Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition
por: Fenerty, Kathleen E., et al.
Publicado: (2019)

Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
por: Dillard, Pierre, et al.
Publicado: (2021)

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
por: de Vries, Natasja L., et al.
Publicado: (2023)

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
por: Wang, Wei, et al.
Publicado: (2015)

Antibody‐dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant natural killer T cells
por: Mise, Naoko, et al.
Publicado: (2016)

Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer
por: Shang, Yufeng, et al.
Publicado: (2019)

Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer
por: Sivori, Simona, et al.
Publicado: (2020)

Harnessing natural killer cells to develop next‐generation cellular immunotherapy
por: Liu, Siyao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d7sv436amudg6nfgc0kl5b3sjn